Drug intelligence / Profile preview

SBX-1988

Development stage: Preclinical
Lead developer: Stramsen Biotech
Administration: Oral

Overview

**SBX-1988** is a Stramsen Biotech plant-derived herbal drug candidate for **diabetes mellitus**. It is described as an oral brown suspension formulated from a mixture of tropical medicinal plants with pharmaceutical excipients; reported phytochemical constituent classes include alkaloids, terpenoids, flavonoids, and essential oils. Its specific molecular targets and mechanism of action have not been publicly disclosed. The candidate has been listed in Stramsen Biotech's metabolic-disease pipeline and is being advanced toward clinical development.

Other names: SBX 1988SBX1988SBX-1988

Beyond the preview

Go deeper on SBX-1988.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SBX-1988.

Explore the full profile